Delving into the Latest Updates on University of South China with Synapse

Overview

Tags

Infectious Diseases

Nervous System Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Recombinant protein

Genetically engineered subunit vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	3
Nervous System Diseases	2
Endocrinology and Metabolic Disease	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	4
Recombinant protein	1
Genetically engineered subunit vaccine	1

Top 5 Target	Count

c-Met(Hepatocyte growth factor receptor)	1
IL-12(Interleukin-12)	1
Ag85B-ESAT-6 x Lipoproteins	1
5-HT1A receptor x 5-HT1D receptor x MTNR1A x MTNR1B	1
SIK1(salt inducible kinase 1)	1

Predictive model and promoting mechanism of compliance in cardiac rehabilitation in elderly patients with coronary heart disease with reduced intrinsic ability - Predictive model and promoting mechanism of compliance in cardiac rehabilitation in elderly patients with coronary heart disease with reduced intrinsic ability

Start Date01 Sep 2023

Sponsor / Collaborator

University of South China

ChiCTR2300070484 / SuspendedPhase 1IIT

Detection of plasma non-coding RNA in patients with premature coronary heart disease

Start Date01 May 2023

Sponsor / Collaborator

University of South China

100 Clinical Results associated with University of South China

Login to view more data

0 Patents (Medical) associated with University of South China

Login to view more data

21,347

Literatures (Medical) associated with University of South China

01 Feb 2025·Separation and Purification Technology

A self-driven solar coupling system with activated carbon felt cathode for resourcefully purifying uranium and organic contaminated water

Author: Wang, Xu ; Guo, Lulin ; Liu, Yilin ; Zhang, Qingyan ; Zhang, Qingsong ; Wang, Jiachen ; Zeng, Qingyi

With the continuous development of nuclear energy, it becomes increasingly important to recover uranium from the radioactive wastewater, in which various organics may combine with uranyl ions (UO²⁺₂) to form refractory complexes.Developing highly active cathode materials for uranium reduction is essential to improve the performance of self-driven solar coupling system (SSCS) in treating complex radioactive wastewater.In this study, an activated carbon felt (ACF) cathode is prepared by anodizing carbon felt (CF) in NaOH solution to adjust the surface morphol. and functional groups.The ACF is then used in a SSCS combined with a TiO₂ nanorods array (TNA) photoanode for the efficient recovery of uranium and the rapid degradation of organic pollutants with simultaneous electricity generation.Compared to CF, the functionalized ACF with oxygen-containing functional groups, provides sufficient sites for UO²⁺₂ adsorption and facilitates the charge separationThe SSCS with the ACF cathode exhibits removal ratios of approx. 99.9 % for tetracycline hydrochloride (TCH) and UO²⁺₂, with removal rates of ∼ 0.025 and ∼ 0.154 min^-1, resp.In contrast, the SSCS with the CF cathode achieves removal rates of ∼ 0.006 and ∼ 0.026 min^-1.Addnl., a maximum power d. of 0.94 mW·cm^-2 with a fill factor of 23.36 % is achieved.After 20 cycles, the system maintains removal ratios of 99.1 % for TCH and 98.2 % and UO²⁺₂.Intensive investigation also reveals that the system functions robustly in treating complex wastewater with a complicated condition of pH, co-exited ions, and various pollutant concentrationsFurthermore, efficient removal of organics and uranium is also achieved from polluted seawater or under real sunlight illumination.This paper presents a simple method to prepare low-cost, highly active and stable cathodes for uranium reduction in an easy-to-operated, energy-saving and economical solar-driven system.

01 Feb 2025·Separation and Purification Technology

Rational construction of S-scheme ZnIn2S4/g-C3N4 heterojunction for effective sacrificial agent-free uranium photocatalysis in air

Author: Liang, Beichao ; Chen, Lijie ; Dai, Zhongran ; Zhang, Weilin ; Gao, Yuan ; Li, Le

Photocatalysis holds promise for extracting uranium from aqueous solutionNevertheless, conventional approaches generally rely on sacrificial agents and anaerobic conditions to maintain photocatalytic efficiency, which increases costs and causes secondary pollution.Herein, we introduce the design and synthesis of an S-scheme ZnIn₂S₄/g-C₃N₄ (ZISCN) heterojunction photocatalyst for the efficient removal of uranium via in-situ generating ZnIn₂S₄ on g-C₃N₄.Photoelec. characterization and theor. calculation indicate that ZISCN boosts the absorption of visible light and promotes the effective separation and migration of charge carriers by forming an internal elec. field (IEF) at the S-scheme heterojunction interface.This configuration integrates the strong reducing electrons of g-C₃N₄ and the potent oxidation holes of ZnIn₂S₄.Consequently, the as-synthesized ZISCN can efficiently remove uranium under an air atm. without the need for sacrificial agents and anaerobic conditions.The achieved U(VI) removal rate of 94.8 % surpasses that of ZnIn₂S₄ and g-C₃N₄ individually.Moreover, the photocatalytic extraction of U(VI) by ZISCN photocatalyst demonstrated excellent stability and anti-interference performance.After five cycles, the U(VI) removal rate remained above 85 %.Mechanism studies reveal that when electrons are generated by light in the ZISCN systems, they can reduce O₂, leading to the formation of reactive species ·O₂/H₂O₂.These species subsequently interact with U(VI), resulting in the precipitation of (UO₂)O₂·2H₂O on the surface of ZISCN.This research provides valuable insights for the design of heterojunction photocatalysts for efficient, sacrificial agent-free uranium removal in ambient air environments.

01 Feb 2025·Combinatorial Chemistry & High Throughput Screening

Current Perspectives of Immunotherapy for Hepatocellular Carcinoma

Article

Author: Lei, Xiaoyong ; Yang, Xiaoyan ; Huang, Sheng ; Liu, Xiaoyi

Abstract:Hepatocellular carcinoma is the sixth most common tumor and the third leading cause of cancer death worldwide. It ranks fourth in the spectrum of malignant tumor incidence and second in the order of death from major malignant tumors in China. Hepatocellular carcinoma is a complex ecosystem containing non-tumor cells (mainly immune-related cells), and its immunotherapy can stimulate the recognition of specific tumor antigens, inhibit the proliferation of cancer cells, and produce over-memory lymphocytes, which can prevent recurrence. So, immunotherapy of hepatocellular carcinoma is increasingly becoming a research hotspot in liver cancer treatment. With the intensive research in recent years, great progress has been made in immunotherapy for hepatocellular carcinoma, including immune checkpoint inhibitors, pericyte therapy, vaccination, and antiviral therapy. In addition, the study found that the therapeutic effect of combination therapy was enhanced compared to monotherapy. This review summarizes the most prominent immunotherapies currently available for the clinical treatment of patients with HCC and the main opportunities and challenges facing HCC research.

1

News (Medical) associated with University of South China

23 Jul 2024

·www.drugs.com

Link Between T2DM, Spinal Degenerative Disorder May Be Method-Dependent

TUESDAY, July 23, 2024 -- The association between type 2 diabetes mellitus (T2DM) and spinal degenerative disorders (SDDs) may be method-dependent, according to a study published online July 3 in The Journal of Bone & Joint Surgery . Ming-Xiang Zou, M.D., Ph.D., from the University of South China in Hengyang, and colleagues examined and compared the association between T2DM and SDD using observational studies and Mendelian randomization (MR) analyses. Data for the observational analyses included 44,972 participants with T2DM and 403,095 without T2DM in cross-sectional studies; 38,234 participants with SDD and 409,833 participants without SDD in case-control studies; and 35,550 participants with T2DM and 392,046 without T2DM in prospective studies. The associations between single-nucleotide polymorphisms with SDD susceptibility obtained using participant data from 407,938 participants in the U.K. Biobank and 227,388 participants from the FinnGen Consortium were included in MR analyses; genetic predisposition to T2DM was obtained from a pooled genome-wide association study involving 1,407,282 individuals. The researchers found that SDD was more likely among participants with T2DM. In logistic regression analysis, T2DM was an independent risk factor for SDD, which was confirmed by the results from the Cox proportional hazard model. The MR analyses demonstrated no causal relationship between T2DM and SDD using single-nucleotide polymorphisms as instruments. In the sensitivity analysis, the lack of such an association was robust and no pleiotropy was seen. "Researchers and clinicians should be cautious in interpreting the association, especially the causal association, between T2DM and SDD," the authors write.

OligonucleotideClinical ResultClinical Study

100 Deals associated with University of South China

Login to view more data

100 Translational Medicine associated with University of South China

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

5

Preclinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

YKL-06-061 ( SIK1 )	Seizures More	Preclinical
LAH-1 ( c-Met )	Non-Small Cell Lung Cancer More	Preclinical
ECP001 ( Ag85B-ESAT-6 x Lipoproteins )	Tuberculosis More	Preclinical
Piromelatine ( 5-HT1A receptor x 5-HT1D receptor x MTNR1A x MTNR1B )	Dyssomnias More	Preclinical
Bacterial biofilms inhibitors(University of South China) ( Phospholipids )	MRSA - Methicillin resistant Staphylococcus aureus infection More	Preclinical